http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20212157-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a8470f22066c0ba2fe50741174c7ab
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40
filingDate 2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e352f61192d0fdf438d7f86ec8a8d3f7
publicationDate 2021-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PE-20212157-A1
titleOfInvention PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
abstract Described herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions can be administered orally, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed are methods of treating migraine-like pain, comprising administering meloxicam and rizatriptan to a human suffering from migraine-like pain. For migraine, these methods may be particularly useful when meloxicam and rizatriptan are administered while the human is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan can be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
priorityDate 2019-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534751
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID769
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19660
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743278
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54677470
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415136092
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407832258
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559376

Total number of triples: 32.